Skip to main content

Table 4 Final Model of Time until LDL Cholesterol Control

From: A Retrospective Cohort Study of the Potency of lipid-lowering therapy and Race-gender Differences in LDL cholesterol control

  Hazard 95% CI  
Characteristic Ratio Lower Upper P value
Gender-race     
Black women 0.66 0.56 0.78 < 0.0001
Black men 0.82 0.69 0.98 0.029
White women 0.75 0.64 0.88 < 0.0001
Baseline LDL cholesterol (quartile)     
Second 0.89 0.78 1.01 0.082
Third 0.67 0.58 0.77 < 0.0001
Fourth 0.48 0.42 0.56 < 0.0001
Total lipid-lowering drug potency     
Low 1.23 1.08 1.41 0.001
High 1.85 1.63 2.1 < 0.0001
LDL checks in first 6 months     
1-2 2.79 2.33 3.35 < 0.0001
3+ 4.41 3.58 5.44 < 0.0001
Age [years]     
61-70 1.1 0.98 1.25 0.114
71-80 1.28 1.11 1.47 0.001
> 80 1 0.84 1.21 0.96
Median neighborhood (per $1000 increase) 1 1 1.01 0.016
Smoking status     
Current 0.99 0.84 1.18 0.934
Not reported 1.04 0.93 1.17 0.512
Vascular disease 0.8 0.7 0.92 0.001
Unrelated comorbidities (per comorbidity) 1.04 1.02 1.06 < 0.0001
Diabetes 0.81 0.72 0.9 < 0.0001
Chronic renal insufficiency 1.26 1.05 1.52 0.012
Insurance type     
Medicaid 0.87 0.72 1.04 0.128
Medicare 0.97 0.86 1.1 0.623
Self pay 0.85 0.42 1.71 0.641
High patient adherence to visits 1.31 1.13 1.51 < 0.0001
Antihypertensive drugs (N) 0.98 0.93 1.02 0.299
Provider type     
Resident 1.15 0.96 1.38 0.117
Other clinician 1.01 0.86 1.19 0.897
Provider race     
Asian 1.07 0.85 1.33 0.57
Black or other 0.99 0.84 1.16 0.877
Female provider 1.03 0.9 1.18 0.645
Provider workload (quartile of annual visits)     
Second 1.02 0.88 1.19 0.788
Third 0.96 0.82 1.12 0.58
Fourth 0.94 0.78 1.14 0.535
Patient visits (quartile of annual visits)     
Second 1.01 0.88 1.16 0.896
Third 1.09 0.95 1.25 0.24
Fourth 1.01 0.87 1.18 0.867